23andMe Bringing Genetic Edge to Pharmaceuticals

March 12 -- Jay Lichter, managing director at Avalon Ventures, and Bloomberg’s Caroline Chen discuss the move by 23andMe into drugmaking and discovery and the role might play in the future of the pharmaceutical industry. They speak on “Bloomberg West.”